These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Afzal MZ; Shirai K J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044 [TBL] [Abstract][Full Text] [Related]
12. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650 [TBL] [Abstract][Full Text] [Related]
13. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293 [TBL] [Abstract][Full Text] [Related]
14. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385 [TBL] [Abstract][Full Text] [Related]
15. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058 [TBL] [Abstract][Full Text] [Related]
17. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498 [TBL] [Abstract][Full Text] [Related]
18. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report. Chitnis SD; Seim NB; Kendra K J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387 [TBL] [Abstract][Full Text] [Related]
19. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience. Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. Masoud SJ; Hu JB; Beasley GM; Stewart JH; Mosca PJ Ann Surg Oncol; 2019 Dec; 26(13):4633-4641. PubMed ID: 31414290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]